I expect shares of Amgen (NSDQ: AMGN), the world’s largest biotech company, to rise above $180 in the next few weeks based on a reliable seasonal pattern. The stock tends to rise in price during the month prior to the release of its earnings report, which is due out on… Read More

Back in June I recommended the purchase of two small-cap tech stocks (“Top Tech Takeover Targets”), one of which – Synaptics Inc. (SYNA) – I subsequently sold last month after discovering that officers of the company have been huge sellers of the stock this year. We booked a… Read More

I have been increasingly concerned about the action in the overall stock market for some time, and the action on yesterday (8/24) afternoon and this morning suggested that it’s time to buy some portfolio protection.  So I am recommending the purchase of the ProShares Ultrashort ETF (BIS) as a hedge for a diversified… Read More

Seres Therapeutics (Nasdaq: MCRB), a research stage biotech company seeking to use the human microbiome to treat gut-related illnesses, expanded its losses in its most recent quarter.  The company reported a loss of $27.8 million, or 70 cents per share, and $3 million in revenues for the quarter as it… Read More

This morning Ekso Bionics Holdings (EKSO) announced it will raise $15 million via a secondary offering of 3,750,000 million shares of common stock at a price of $4.00 per share. This announcement was accompanied by confirmation that the company’s stock has been approved for listing on the Nasdaq Capital… Read More

I am increasing the Buy limit on Opko Health (OPK), a diversified health care company focused on renal diseases and precise laboratory testing, from to $11 to $12 as the company beat its quarterly earnings expectation and gave upbeat guidance on its August 8 earnings release.  I am leaving the… Read More

[from the 8/8/2016 issue of Breakthrough Tech Weekly]FireEye (NSDQ: FEYE) tumbled after reporting another difficult quarter, which seems to be a recurring theme for the company. Second quarter revenue came in at $175 million, up 18.9% year-over-year but still well below the expected $181 million. Billings also came up short… Read More

Although it was only two months ago that I identified Synpatics (SYNA) as one of my two “Top Tech Takeover Targets”, recently released insider trading activity by the company’s officers suggest they don’t have much confidence in the company’s future. Over the past six months, every one of the… Read More

I am recommending the sale of Novo Nordisk NYSE: (NVO) and Emergent BioSolutions (NYSE: EBS).  Both companies failed to meet expectations and are likely to run into further headwinds as the biotech and healthcare dynamic changes gears and price cutting pressure in the U.S. starts to gather steam.Emergent BioSolutions Inc. Read More

Shares of Cerus Corp. (Nasdaq: CERS) and Rollins Inc. (NYSE: ROL) moved higher on July 29 (and are higher in this morning’s trading) in response to the developing story in the state of Florida with regard to the Zika virus.  Rollins Inc. is the leading global pest control company, operating… Read More